Log in to your Inderes Free account to see all free content on this page.
Create account

Mendus

5.90 SEK

-1.34 %

Less than 1K followers

IMMU

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

-1.34 %
+8.26 %
+22.41 %
+5.36 %
+1.90 %
+10.07 %
-77.45 %
-94.04 %
-95.54 %

Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.

Read more
Market cap
369.25M SEK
Turnover
129.12K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.8.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

ShowingAll content types
Third party research

Mendus: Clinical expansion initiated; Q126 results - Edison

Mendus’s Q126 results reflect the execution of its expanded clinical strategy for vididencel, with the key highlight being the launch of the Phase I VITAL-CML trial in chronic myeloid leukaemia (CML), marking the start of clinical development in this...

Mendus

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

Mendus: CML programme commences - Edison

Mendus has announced the launch of its chronic myeloid leukaemia (CML) programme for lead immunotherapy candidate, vididencel. Preparations have been completed and regulatory clearance has been received for the Phase I VITAL-CML study, which will assess...

Mendus
Third party research

Mendus: Agreement to advance AML programme - Edison

Mendus has announced a new clinical collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) to support the Phase Ib DIVA trial, evaluating lead cancer vaccine vididencel in chemo-unfit acute myeloid leukaemia (AML) patients. The ...

Mendus
Forum discussions
I’ve created a dedicated thread for Mendus, but my English is poor and I don’t know the industry at all, so there are bound to be mistranslations and misunderstandings. I looked up information on Inderes’ site, especially from the extensive report. Naturally, I googled for info and...
7/23/2024, 7:30 PM
by Sijoittaja-alokas
11
Tässä on Antin tuoreet kommentit Mendusin tuoreesta ilixadenceli-tutkimuksen yhteistyöstä. Mendus announced on Tuesday that the company will start a new ilixadencel trial in collaboration with the French cancer center Institut Bergonié. The trial will combine ilixadencel with the...
7/24/2024, 4:39 AM
by Sijoittaja-alokas
3
An interesting discovery, but so are many other Swedish biopharma/biotech firms. You can put money into these like a lottery ticket and maybe one eventually succeeds, while the rest engage in endless dilution of their share capital and wash away investors’ money. The discussion surrounding...
7/23/2024, 8:38 PM
by Acumen
3
MFN – 5 May 25 Mendus AB (publ): Mendus strengthens late-stage clinical developmen... Mendus AB ('Mendus' publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the appointment of Tariq Mughal, MD FRCP FRCPath, as Chief...
5/5/2025, 12:38 PM
by Clark kent
2
Tässä on Antin yhtiöraportti Menduksen Q2:n jälkeen. For Mendus, Q2’24 marked the start of the pivotal CADENCE trial in acute myeloid leukemia (AML). The company also announced plans to restart clinical development of ilixadencel in soft tissue sarcomas (STS). In parallel, Mendus...
8/26/2024, 6:40 PM
by Sijoittaja-alokas
2
Mendus published its second-quarter report on Friday, August 23. In an interview with Antti, CEO Erik Manting summarizes what happened during the second quarter, highlights the key achievements of the CADENCE trial, and discusses the new study for the drug Ilixadencel. Inderes Mendus...
8/24/2024, 12:03 PM
by Sijoittaja-alokas
2
What’s weighing on Mendu?
11/21/2024, 3:38 PM
by Juksut
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.